drugset / Trial / NCT00946985

28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

NCT00946985

Phase 4 Terminated 163 enrolled Ortho-McNeil Janssen Scientific Affairs, LLC
RandomizedParallel-groupOpen-labelPrevention

Summary

The study will assess the use of paliperidone palmitate compared with oral risperidone in delaying time to relapse in patients recently diagnosed with schizophrenia who are at high risk of relapse.

Timeline

Start
2009-06
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Risperidone Other / unclassified 2 mg Oral
Comparator Risperidone Other / unclassified 4 mg Oral
Comparator Risperidone Other / unclassified 6 mg Oral
Comparator Risperidone Other / unclassified 8 mg Oral
Subject paliperidone palmitate Unknown 50 mg Other
Subject paliperidone palmitate Unknown 75 mg Other
Subject paliperidone palmitate Unknown 100 mg Other
Subject paliperidone palmitate Unknown 150 mg Other

Indications